Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations

NCT05651672 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Cancer

Interventions

DRUG: Pemigatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital